argenx SE
NASDAQ · ARGX·Breda, Netherlands·Large-cap·Approved
FcRn antibody pioneer with Vyvgart (efgartigimod) approved across generalized myasthenia gravis, CIDP, and expanding into additional autoimmune indications. The company's broad pipeline leverages its immunology platform targeting FcRn and complement pathways across neurology and rare disease.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| argenx Corporate Presentation March 2026 | Corporate overview | March 1, 2026 | 25 |